Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Charité – Universitätsmedizin Berlin at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Charité – Universitätsmedizin Berlin brings 8 presentations to ASH 2026 in New Orleans. Its program spans leukemia, lymphoma and myeloma, with a focus on transplant outcomes. Research covers CRISPR screens for myeloma drug resistance and a chemotherapy-free first-line lymphoma trial.

OrganizationASH 2026 Attendance
Hospitals & cancer centres
University hospital and joint medical faculty of Berlin's Free and Humboldt universities, one of Europe's largest.
Talk
Sat Dec 12
2:00pm–3:15pm
AML Immune Escape Mechanisms Driving Post-Therapy Relapse
Why acute myeloid leukemia returns after chemotherapy, donor transplant, or immunotherapy, traced to leukemia evolution and exhausted T cells in the marrow.
Leukemias · AI & data

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Charité – Universitätsmedizin Berlin

Tell us what you sell and we’ll find the people at Charité – Universitätsmedizin Berlin most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction